骨关节炎治疗市场：依药物类别、给药途径、疾病类型、通路和地区划分

预计到2026年，骨关节炎治疗市场规模将达到84.5亿美元，2033年将达到177.5亿美元。预计从2026年到2033年，该市场将以11.2%的复合年增长率成长。

骨质疏鬆症是一种全身性疾病，其特征是骨量减少和骨组织微结构劣化，导致骨骼脆弱，增加髋部、脊椎和腕部骨折的风险。由于其全球高发病率，骨质疏鬆症被认为是一个严重的公共卫生问题，会导致身体残疾和疼痛。骨质疏鬆症的病理生理机转在于骨吸收和骨形成之间的失衡。在骨质疏鬆症中，骨吸收超过骨形成，造成负平衡，导致骨质净减少，骨折风险也相应增加，最终导致畸形和慢性疼痛。如果伤害性疼痛持续至少三个月，则被认为是慢性疼痛。

• 骨形成与骨吸收之间的失衡可能是由以下一个或多个因素造成的：
• 重塑单元内骨吸收增加。
• 重塑单元内骨形成减少（不完全连接）。

市场动态

市场主要企业正专注于内部成长策略，例如收购，预计将推动全球骨关节炎治疗市场在预测期内的成长。例如，2022年8月15日，投资服务公司Gurnet Point Capital和医疗保健投资公司Patient Square Capital宣布完成对生技公司Radius Health, Inc.的收购。 Radius的旗舰产品TYMLOS（阿伐洛帕肽）于2017年在美国上市，用于治疗停经后高骨折风险女性的骨质疏鬆症。此次收购将使该公司能够在预测期内进一步扩大其在骨关节炎治疗市场的份额。

然而，使用Ibuprofen和萘普生等非类固醇消炎剂（NSAIDs）治疗骨关节炎疼痛可能导致心血管疾病，预计将阻碍市场成长。例如，2018年6月，欧洲抗风湿病联盟（EULAR）就曾指出，长期使用NSAIDs治疗骨关节炎疼痛会带来心血管疾病风险。

本报告的主要特点

• 本报告对全球骨关节炎治疗市场进行了详细分析，包括预测期（2025-2032 年）的市场规模和复合年增长率，以 2024 年为基准年。
• 此外，它还确定了每个细分市场的潜在商机，并描述了该市场中一系列有吸引力的投资提案。
• 此外，它还提供了有关市场驱动因素和限制因素、机会、新产品发布和核准、市场趋势、区域展望以及主要企业采取的竞争策略的重要见解。
• 本节根据以下参数介绍全球骨关节炎治疗市场主要企业的概况：公司概况、产品系列、主要亮点、财务表现和策略。
• 本报告中的见解将使负责人和企业经营团队能够就未来的产品发布、产品线更新、市场扩张和行销策略做出明智的决策。
• 《全球骨关节炎治疗市场》报告针对该行业的各种相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
• 相关人员可以透过分析全球骨关节炎治疗市场中使用的各种策略矩阵来促进决策。

目录

第一章：分析目标与假设

• 分析目的
• 先决条件
• 简称

第二章 市场展望

• 报告说明
  • 市场定义和范围
• 执行摘要

第三章：市场动态、监管与趋势分析

• 市场动态
• 影响分析
• 主要趋势
• 法规环境
• 产品上市及核准
• PEST分析
• 波特五力分析
• 市场机会
• 法规环境
• 主要进展
• 产业趋势

第四章 全球骨关节炎治疗市场：依药物类别划分（2020-2033 年）

• 止痛药
• 非类固醇消炎剂
• 皮质类固醇
• 玻尿酸
• 处于 III 期临床试验阶段的药物

第五章 全球骨关节炎治疗市场：依给药途径划分（2020-2033 年）

• 口服
• 肠外
• 外用

第六章 全球骨关节炎治疗市场：依疾病类型划分（2020-2033 年）

• 踝关节骨关节炎
• 髋关节骨关节炎
• 膝关节骨关节炎
• 肩关节骨关节炎
• 其他（脊椎骨关节炎、颈椎骨关节炎）

第七章 全球骨关节炎治疗市场：依通路划分（2020-2033 年）

• 医院药房
• 零售药房
• 网路药房

第八章 全球骨关节炎治疗市场：按地区划分（2020-2033 年）

• 北美洲
  • 我们
  • 加拿大
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲
• 欧洲
  • 德国
  • 英国
  • 西班牙
  • 法国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • ASEAN
  • 亚太其他地区
• 中东
  • 海湾合作委员会国家
  • 以色列
  • 其他中东国家
• 非洲
  • 南非
  • 北非
  • 中非

第九章 竞争情势

• Pfizer, Inc.
• Abbott
• Eli Lilly and Company
• ABIOGEN PHARMA SpA
• Horizon Therapeutics plc
• Ferring BV
• Merck Sharp & Dohme Corp.
• Medivir
• Bioventus
• Sanofi
• Regeneron
• GlaxoSmithKline Plc.
• Johnson & Johnson Private Limited
• Bayer AG
• Novartis AG
• Ferring BV
• Pacira Pharmaceuticals, Inc
• Zimmer Biomet
• OrthogenRx, Inc.
• PHARMED LTD

第十章 分析师建议

• 机会
• 分析师意见
• Coherent Opportunity Map (COM)

第十一章 参考文献与分析方法

• 参考
• 分析方法
• 关于 Coherent Market Insights

Osteoarthritis Drugs Market is estimated to be valued at USD 8.45 Bn in 2026 and is expected to reach USD 17.75 Bn by 2033, growing at a compound annual growth rate (CAGR) of 11.2% from 2026 to 2033.

Osteoporosis is a systemic disorder characterized by decreased bone mass and microarchitectural deterioration of bone tissue, leading to bone fragility and increased susceptibility to fractures of the hip, spine, and wrist. Due to its important prevalence worldwide, osteoporosis is considered a serious public health concern associated with disability and pain. The pathophysiology of osteoporosis is an imbalance between bone resorption and bone formation. In osteoporosis, bone resorption takes place to a greater extent than bone formation, so a negative balance occurs with a net loss of bone and an accompanying increasing risk of fractures, resulting in deformity and chronic pain. Nociceptive pain is considered to be chronic when it has been present for at least 3 months.

• The imbalance between bone formation and bone resorption might occur as a result of one or a combination of the following factors:
• Increased bone resorption within a remodeling unit.
• Decreased bone formation within a remodeling unit (incomplete coupling)

Market Dynamics

Key players in the market are focused on organic growth strategies such as acquisitions, which is expected to drive the global osteoarthritis drugs market growth over the forecast period. For instance, on August 15, 2022, Gurnet Point Capital, an investment service company and Patient Square Capital, a healthcare investment company, announced the completion of their acquisition of Radius Health, Inc., a Biotechnology Company. Radius' lead product, TYMLOS (abaloparatide) was launched in the U.S. in 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture. This acquisition will help the company in further expansion in the osteoarthritis drugs market over the forecast period.

However, use of Non-steroidal Anti-Inflammatory Drugs (NSAIDs) such as ibuprofen and naproxen in pain management of osteoarthritis can cause cardiovascular diseases, which in turn is expected to hinder the market growth. For instance, in June 2018, the European League against Rheumatism (EULAR) stated the risk of cardiovascular diseases with the regular use of NSAIDs in the treatment of osteoarthritis pain.

Key features of the study

• This report provides an in-depth analysis of the global osteoarthritis drugs market, market size (USD Bn), and compound annual growth rate (CAGR (%)) for the forecast period: 2026 - 2033, considering 2025 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
• It profiles key players in the global osteoarthritis drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
• Key players covered as a part of this study include Pfizer, Inc., Abbott, Eli Lilly and Company, ABIOGEN PHARMA S.p.A, Horizon Therapeutics plc, Ferring B.V., Merck Sharp & Dohme Corp., Medivir, Bioventus, Sanofi, Regeneron, GlaxoSmithKline Plc., Johnson & Johnson Private Limited, Bayer AG, Novartis AG, Ferring B.V., Pacira Pharmaceuticals, Inc, Zimmer Biomet, OrthogenRx, Inc. and PHARMED LTD.
• Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future drug launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
• The global osteoarthritis drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for drug market, research and consulting firms, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global osteoarthritis drugs market

Market Segmentation

• Drug Class Insights (Revenue, USD Bn, 2026 - 2033)
  • Analgesics
  • Non-steroidal Anti-Inflammatory Drugs
  • Corticosteroids
  • Hyaluronic Acid
  • Phase III Drugs
• Route of Administration Insights (Revenue, USD Bn, 2026 - 2033)
  • Oral
  • Parenteral
  • Topical
• Disease Type Insights (Revenue, USD Bn, 2026 - 2033)
  • Ankle Osteoarthritis
  • Hip Osteoarthritis
  • Knee Osteoarthritis
  • Shoulder Osteoarthritis
  • Others (Spinal Osteoarthritis and Cervical Osteoarthritis)
• Distribution Channel Insights (Revenue, USD Bn, 2026 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Regional Insights (Revenue, USD Bn, 2026 - 2033)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • North Africa
  • Central Africa
  • South Africa
• Key Players Insights
  • Pfizer, Inc.
  • Abbott
  • Eli Lilly and Company
  • ABIOGEN PHARMA S.p.A
  • Horizon Therapeutics plc
  • Ferring B.V.
  • Merck Sharp & Dohme Corp.
  • Medivir
  • Bioventus
  • Sanofi
  • Regeneron
  • GlaxoSmithKline Plc.
  • Johnson & Johnson Private Limited
  • Bayer AG
  • Novartis AG
  • Ferring B.V.
  • Pacira Pharmaceuticals, Inc
  • Zimmer Biomet
  • OrthogenRx, Inc.
  • PHARMED LTD

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Overview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Osteoarthritis Drugs Market, By Drug Class
  • Global Osteoarthritis Drugs Market, By Route of Administration
  • Global Osteoarthritis Drugs Market, By Disease Type
  • Global Osteoarthritis Drugs Market, By Distribution Channel
  • Global Osteoarthritis Drugs Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Market Opportunities
• Regulatory Scenario
• Key Developments
• Industry Trend

4. Global Osteoarthritis Drugs Market, By Drug Class, 2020-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Analgesics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
• Non-steroidal Anti-Inflammatory Drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
• Corticosteroids
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
• Hyaluronic Acid
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
• Phase III Drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)

5. Global Osteoarthritis Drugs Market, By Route of Administration, 2020-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
• Parenteral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
• Topical
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)

6. Global Osteoarthritis Drugs Market, By Disease Type, 2020-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Ankle Osteoarthritis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
• Hip Osteoarthritis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
• Knee Osteoarthritis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
• Shoulder Osteoarthritis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
• Others (Spinal Osteoarthritis and Cervical Osteoarthritis)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)

7. Global Osteoarthritis Drugs Market, By Distribution Channel, 2020-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)

8. Global Osteoarthritis Drugs Market, By Region, 2020 - 2033, Value (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2033, Value (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Disease Type, 2020 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Value (USD Bn)
  • Market Size and Forecast, By Drug Class, 2020 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Disease Type, 2020 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Value (USD Bn)
  • Market Size and Forecast, By Drug Class, 2020 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Disease Type, 2020 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Value (USD Bn)
  • Market Size and Forecast, By Drug Class, 2020 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Disease Type, 2020 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Value (USD Bn)
  • Market Size and Forecast, By Drug Class, 2020 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Disease Type, 2020 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Value (USD Bn)
  • Market Size and Forecast, By Drug Class, 2020 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Disease Type, 2020 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

9. Competitive Landscape

• Pfizer, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Abbott
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Eli Lilly and Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• ABIOGEN PHARMA S.p.A
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Horizon Therapeutics plc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Ferring B.V.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merck Sharp & Dohme Corp.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Medivir
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bioventus
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sanofi
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Regeneron
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• GlaxoSmithKline Plc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Johnson & Johnson Private Limited
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bayer AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Ferring B.V.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Pacira Pharmaceuticals, Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Zimmer Biomet
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• OrthogenRx, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• PHARMED LTD
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us